Gold bars to be exempt from tariffs, White House clarifies
LONDON - Investment management corporation BlackRock (NYSE:BLK), Inc. has reported a 1.62% holding in Mural Oncology plc, according to a disclosure made to the Irish Takeover Panel on Monday. The disclosure, which is part of the regulatory requirements under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, outlines BlackRock’s position in the company as of June 6, 2025.
BlackRock’s interest in Mural Oncology consists of 279,813 ordinary shares, representing 1.62% of the company’s issued share capital. The firm also holds a negligible number of cash-settled derivatives on the company’s stock, amounting to 15 shares. No short positions have been reported by BlackRock in relation to Mural Oncology’s securities.
The disclosure also noted a return of stock on loan involving 7,100 ordinary shares, a transaction that does not affect the overall percentage of BlackRock’s holdings in the oncology-focused company.
The investment manager has not disclosed any dealings in other classes of relevant securities of Mural Oncology. Additionally, BlackRock confirmed that there are no indemnity or option arrangements, or any agreements, arrangements, or understandings related to the voting rights of Mural Oncology’s relevant securities under any options or derivatives.
This announcement comes amid no reported cash offers or possible cash offers for Mural Oncology, and it does not indicate any further intentions by BlackRock regarding its investment in the company.
The information in this article is based on a press release statement and is intended to provide investors and the market with regulatory compliance information regarding BlackRock’s interests and positions in Mural Oncology plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.